Xylo Bio
Transforming lives with targeted neurotherapeutics
At a glance
-
Development stage
Early stage research / proof-of-concept
-
Investment stage
Series A
-
UNSW affiliation
Co-located company
-
Technology readiness level
TRL 4
Xylo is pioneering next-generation therapeutics designed to rewire neural circuits and restore brain function.
By combining advanced neuroscience with computational discovery, Xylo is developing treatments to revolutionise care for neurological and psychiatric conditions. They aim to deliver breakthrough therapies that address critical unmet needs and improve the lives of patients worldwide.
-
Xylo is building a pipeline of therapies designed to enhance neuroplasticity and address critical gaps in the treatment by harnessing the brain’s ability to rewire and restore function.
Neuroplasticity offers a transformative approach to treating psychiatric and neurological disorders — whereby underlying dysfunctions can be addressed instead of merely managing symptoms — paving the way for long-term recovery.
-
- Patients with psychiatric and neurological disorders deserve better treatments. Xylo are developing innovative mechanism-based therapies to provide effective solutions for these complex conditions.
- By redefining care, Xylo aim to address critical unmet needs and create lasting impact for patients and healthcare systems.
-
- Patients with psychiatric & substance-use disorders
- Individuals with other undisclosed neurological conditions
-
- Xylo has four development programs. Their lead program begins clinical trials in 2026 for major depressive disorder. Xylo’s other programs are in pre-clinical development.
- Secured Series Seed funding led by Tenmile and Main Sequence Ventures.
- Expanding into the US with new HQ while maintaining strong presence on UNSW Kensington campus.
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.